{"meta":{"query_hash":"61eb7b31e46f","filters":{"venue":"Biological Products Prevention Diagnosis Treatment"},"cohort_total":3,"direct_labels_cover":0,"predictions_cover":3,"exported":3,"export_cap":100000,"truncated":false,"label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"permalink":"https://metacan.xera.ac/q/61eb7b31e46f","api":"https://metacan.xera.ac/api/v1/cohort?venue=Biological+Products+Prevention+Diagnosis+Treatment"},"results":[{"id":"W2888948683","doi":"","title":"Трансплантация фекальной микробиоты: возможные терапевтические подходы и вопросы правового регулирования","year":2015,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Clostridium difficile and Clostridium perfringens research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Fecal bacteriotherapy; Clostridium difficile; Diarrhea; Feces; Medicine; Disease; Intensive care medicine; Microbiology; Immunology; Biology; Gastroenterology; Pathology; Antibiotics","score_opus":0.21527336990834892,"score_gpt":0.37807039167735296,"score_spread":0.16279702176900404,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2888948683","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.9156038,0.049970407,0.000020227895,0.01715862,0.0036275089,0.006269781,0.00037971613,0.00053702464,0.006432923],"genre_scores_gemma":[0.92122835,0.03371556,0.0004538428,0.00036292634,0.0049365344,0.0022564062,0.0014959904,0.00015728165,0.035393108],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9888626,0.0015365616,0.002054116,0.0032800084,0.0018088005,0.0024579465],"domain_scores_gemma":[0.9928675,0.00069901405,0.00068530213,0.0023661566,0.0012738069,0.0021081786],"candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0018952157,0.0016991768,0.002216972,0.0005574458,0.0005280076,0.00030818605,0.0008196556,0.0012019302,0.0038019042],"category_scores_gemma":[0.003747656,0.0012486386,0.0010850367,0.0015107215,0.0008208977,0.00032573333,0.0006892922,0.000961941,0.008827052],"study_design_candidate":"not_applicable","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0054924786,0.06668468,0.15611842,0.001035766,0.0048052943,0.002281094,0.0015775282,0.000116696676,0.01629815,0.0013218689,0.26400375,0.48026428],"study_design_scores_gemma":[0.018355476,0.036142416,0.028369851,0.0011106964,0.0024587847,0.00023549802,0.0016794621,0.00010181211,0.2887514,0.00080786564,0.61962694,0.002359812],"about_ca_topic_score_codex":0.00052911055,"about_ca_topic_score_gemma":0.00008051271,"teacher_disagreement_score":0.47790447,"about_ca_system_score_codex":0.0033000435,"about_ca_system_score_gemma":0.001903155,"threshold_uncertainty_score":0.9995755},"labels":[],"label_agreement":null},{"id":"W2955764585","doi":"","title":"Безопасность биологических препаратов. Сообщение 2. Проблемы безопасности биоподобных препаратов","year":2016,"lang":"ru","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Biosimilar; Pharmacovigilance; Medicine; Infliximab; Interchangeability; Ulcerative colitis; Inflammatory bowel disease; Marketing authorization; Disease; Intensive care medicine; Pharmacology; Drug; Internal medicine; Bioinformatics","score_opus":0.10569599546046901,"score_gpt":0.33729123216130036,"score_spread":0.23159523670083135,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W2955764585","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.55742663,0.17269611,0.0026165561,0.21785572,0.019310804,0.015043684,0.0035696612,0.002193967,0.009286862],"genre_scores_gemma":[0.87638086,0.053867668,0.0040875035,0.0010507467,0.0017700754,0.001533643,0.0003337016,0.00013465628,0.06084113],"study_design_codex":"design_other","study_design_gemma":"not_applicable","domain_scores_codex":[0.9877427,0.0036884,0.0022013714,0.0035977643,0.0003171135,0.002452655],"domain_scores_gemma":[0.993964,0.0019612047,0.0009775499,0.0021207281,0.00049743615,0.00047905665],"candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["metaepi_narrow","insufficient_payload"],"category_scores_codex":[0.0018031723,0.0018709797,0.0023051077,0.00040109336,0.0008309379,0.00015041098,0.0010946995,0.0025312367,0.015421697],"category_scores_gemma":[0.0023125368,0.0010266801,0.001511386,0.0009671995,0.002108088,0.00037690136,0.0006752801,0.0006404527,0.005118563],"study_design_candidate":"design_other","study_design_consensus":null,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0015947182,0.016264455,0.038381733,0.00017305212,0.0040683667,0.00016169193,0.00017426789,9.5324145e-7,0.070494056,0.008336676,0.05432185,0.8060282],"study_design_scores_gemma":[0.0067089503,0.010722539,0.03260662,0.00081029884,0.0013035992,0.00009599084,0.000113482776,0.0000015753492,0.21978779,0.0042450326,0.7218658,0.0017383496],"about_ca_topic_score_codex":0.00014102395,"about_ca_topic_score_gemma":0.0000766269,"teacher_disagreement_score":0.8042898,"about_ca_system_score_codex":0.0011119698,"about_ca_system_score_gemma":0.00038510893,"threshold_uncertainty_score":0.9994035},"labels":[],"label_agreement":null},{"id":"W4362674372","doi":"10.30895/2221-996x-2023-23-1-26-41","title":"Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain","year":2023,"lang":"en","type":"article","venue":"Biological Products Prevention Diagnosis Treatment","topic":"Poxvirus research and outbreaks","field":"Immunology and Microbiology","cited_by":3,"is_retracted":false,"has_abstract":true,"route_ca_aff":false,"route_ca_fund":false,"route_ca_venue":false,"route_about_ca":true,"ca_institutions":"","funders":"","keywords":"Medicine; Vaccinia; Smallpox; myalgia; Chills; Smallpox vaccine; Adverse effect; Vaccination; Modified vaccinia Ankara; Immunogenicity; Virology; Attenuated vaccine; Immunology; Surgery; Internal medicine; Immune system","score_opus":0.08164719609911085,"score_gpt":0.3061261695840588,"score_spread":0.22447897348494794,"validation_status":"score_only:v0-immature-baseline","prediction":{"id":"W4362674372","genre_codex":"empirical","genre_gemma":"empirical","domain_codex":null,"domain_gemma":null,"model_version":"codex-gemma-dda1882f352a","genre_candidate":"empirical","genre_consensus":"empirical","domain_candidate":null,"domain_consensus":null,"prediction_status":"machine_predicted_unvalidated","genre_scores_codex":[0.99092895,0.001986476,0.000037915313,0.005017257,0.00015775356,0.0013273602,0.0002672241,0.000109565735,0.00016751672],"genre_scores_gemma":[0.9944989,0.0034659628,0.000030265965,0.000105548264,0.000054093867,0.0004123169,0.00087752595,0.000010015057,0.00054535444],"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","domain_scores_codex":[0.99768656,0.00090255635,0.00042694958,0.00053046766,0.0000755708,0.00037789796],"domain_scores_gemma":[0.9986777,0.0005747276,0.00016394387,0.00045948586,0.00008870109,0.000035444817],"candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00088444474,0.0002459701,0.00036021176,0.000116946336,0.00030281363,0.000018597984,0.00018617124,0.0002095844,0.00030322603],"category_scores_gemma":[0.0006523172,0.00013292723,0.00014875256,0.00038618804,0.00011753031,0.00004918605,0.00008997364,0.00015857388,0.00015073187],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_system_candidate":false,"about_ca_system_consensus":false,"study_design_scores_codex":[0.0031996612,0.003297475,0.013775383,0.000041285548,0.0008167202,0.000012129419,0.00024115815,0.0002956408,0.84942424,0.003917606,0.005058204,0.1199205],"study_design_scores_gemma":[0.0053069224,0.006465153,0.42912483,0.00007056297,0.000106249056,0.0000070688407,0.000080337166,0.00040532247,0.54837483,0.00060624833,0.009122848,0.00032962844],"about_ca_topic_score_codex":0.00007841454,"about_ca_topic_score_gemma":0.000035279856,"teacher_disagreement_score":0.41534945,"about_ca_system_score_codex":0.00008419871,"about_ca_system_score_gemma":0.00006998359,"threshold_uncertainty_score":0.5420615},"labels":[],"label_agreement":null}]}